Communiqués Hikma Pharmaceuticals PLC

Actions

HIK

GB00B0LCW083

Produits pharmaceutiques

Temps réel estimé 09:11:43 21/08/2026 Varia. 5j. Varia. 1 janv.
1 615,00 GBX -0,55% Graphique intraday de Hikma Pharmaceuticals PLC -1,16% +4,77%

Communiqués

11/08 Hikma Pharmaceuticals : advances climate progress with first solar energy agreement PU
22/07 Inspired at Hikma: Purpose-driven leadership, developing talent and building for growth. Meet Kristy Ronco PU
23/06 Behind Better Health: Hikma's People PU
22/06 Hikma Pharmaceuticals : welcomes FDA approval of Guardant360® Liquid CDx PU
15/06 Supreme Court Addresses Induced Infringement Claims In Hikma v. Amarin AQ
05/06 Hikma comments on Supreme Court of the United States unanimous decision in favour of Hikma AQ
05/06 Hikma Pharmaceuticals puts access to medicines at the heart of its sustainability strategy, reaching 222 million patients worldwide AQ
04/06 Hikma Pharmaceuticals : comments on Supreme Court of the United States’ unanimous decision in favour of PU
04/06 Hikma Pharmaceuticals : puts access to medicines at the heart of its sustainability strategy, reaching 222 million patient... PU
14/05 Inspired at Hikma: Career growth, leadership and social impact. Meet Zeena Murad PU
08/05 Working at Hikma’s Zagreb R&D hub: meet Nera Marjanovic PU
08/05 Hikma Pharmaceuticals : Why the world needs more companies like Hikma. By Said Darwazah, Chief Executive Officer PU
05/05 Hikma Pharmaceuticals : and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) C... PU
28/04 Hikma Pharmaceuticals : announces settlement agreement for VYNDAMAX® (tafamidis) PU
23/04 Hikma Pharmaceuticals : Results of our 2026 AGM PU
23/04 Hikma Pharmaceuticals : Special Business passed at AGM PU
23/04 Hikma Pharmaceuticals : Trading update April 2026 PU
23/04 Hikma Pharmaceuticals : reiterates full year 2026 guidance following encouraging start to the year PU
16/04 Putting patients first through quality: a Q&A with Tyson Ardo, Associate Vice President, Quality PU
18/03 Hikma Pharmaceuticals : Investing in R&D to drive high-value pipeline delivery PU
18/03 Hikma Pharmaceuticals : Investing in manufacturing excellence at Hikma PU
18/03 Hikma Pharmaceuticals : Investing in MENA to expand access and drive growth PU
18/03 Hikma Pharmaceuticals : Investing in strategic partnerships driving growth in the US and MENA PU
11/03 Hikma Pharmaceuticals : launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US PU
11/03 Hikma Pharmaceuticals : R&D. Innovation in formulation development. Meet Hamza Qassim PU
Aucun résultat pour cette recherche